A recent study found that a selective APRIL blockade in a mouse model of lupus reduces serum IgA and IgM levels and ameliorates lupus nephritis by decreasing proteinuria and renal injury [25]. This evidence concerns the gene TNFSF13 and systemic lupus erythematosus.